Compare EIM & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIM | LYEL |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 499.9M | 556.1M |
| IPO Year | 2002 | 2021 |
| Metric | EIM | LYEL |
|---|---|---|
| Price | $9.92 | $24.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $30.60 |
| AVG Volume (30 Days) | ★ 146.8K | 76.4K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8,712.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.41 | $0.39 |
| 52 Week High | $10.54 | $45.00 |
| Indicator | EIM | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 58.15 | 59.93 |
| Support Level | $9.86 | $21.27 |
| Resistance Level | $10.02 | $27.30 |
| Average True Range (ATR) | 0.10 | 1.65 |
| MACD | 0.03 | 0.41 |
| Stochastic Oscillator | 95.56 | 90.43 |
Eaton Vance Municipal Bond Fund is a non-diversified closed-end management investment company. It consists of Municipal bond fund, California municipal bond fund, and New York municipal bond fund. The company's investment objective is to provide current income exempt from regular federal income tax, alternative minimum tax, and taxes in specified states. Its investment plan is to invest in higher quality bonds.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.